Table 1.

Annual trends of JR-NET 4 data

	2015 (n = 10,257)	2016 (n = 11,019)	2017 (n = 12,551)	2018 (n = 13,873)	2019 (n = 15,530)	Total (n = 63,230)
Age, mean (SD)	66.0 (14.6)	66.3 (14.6)	66.9 (14.7)	67.4 (14.8)	67.9 (14.8)	67.0 (14.7)
Female, n (%)	5,049 (49.3)	5,610 (50.9)	6,382 (50.9)	6,998 (50.5)	7,717 (49.8)	31,756 (50.3)
mRS, median (IQR)	1 (1-2)	1 (1-2)	1 (1-2)	1 (1-2)	1 (1-2)	1 (1-2)
Procedures
Aneurysm treatment, n (%)	4,231 (41.3)	4,599 (41.7)	5,179 (41.3)	5,554 (40.1)	5,865 (37.8)	25,428 (40.2)
Dome embolization, n (%)	3,934 (38.4)	4,334 (39.3)	4,914 (39.2)	5,266 (38.0)	5,589 (36.0)	24,037 (38.0)
Parental artery occlusion, n (%)	297 (2.9)	265 (2.4)	265 (2.1)	288 (2.1)	276 (1.8)	1,391 (2.2)
Angioplasty/stenting, n (%)	2,365 (23.0)	2,359 (21.5)	2,611 (20.9)	2,752 (19.9)	3,126 (20.1)	13,213 (20.9)
Carotid artery stenting, n (%)	1,846 (18.0)	1,862 (16.9)	2,016 (16.1)	2,117 (15.3)	2,356 (15.2)	10,197 (16.1)
Intracranial artery, n (%)	259 (2.5)	216 (2.0)	286 (2.3)	299 (2.2)	391 (2.5)	1,451 (2.3)
Extracranial artery, n (%)	260 (2.5)	281 (2.6)	309 (2.5)	336 (2.4)	379 (2.4)	1,565 (2.5)
Brain & spine AVM embolization, n (%)	365 (3.6)	302 (2.7)	317 (2.5)	361 (2.6)	422 (2.7)	1,767 (2.8)
DAVF embolization	545 (5.3)	618 (5.6)	654 (5.2)	684 (4.9)	747 (4.8)	3,248 (5.1)
Tumor embolization	453 (4.4)	517 (4.7)	554 (4.4)	601 (4.3)	620 (4.0)	2,745 (4.3)
Reperfusion therapy for acute ischemic stroke, n (%)	1,757 (17.1)	2,126 (19.3)	2,689 (21.4)	3,296 (23.8)	4,085 (26.3)	13,953 (22.1)
Practitioner
Senior trainers, JSNET-certified, median (IQR)	1 (0-1)	1 (0-1)	1 (0-1)	1 (0-1)	1 (0-1)	1 (0-1)
Specialists, JSNET-certified, median (IQR)	1 (1-2)	1 (1-2)	1 (1-2)	1 (1-2)	1 (1-2)	1 (1-2)
Non-specialists, median (IQR)	1 (1-2)	2 (1-2)	2 (1-2)	2 (1-2)	2 (1-2)	2 (1-2)

JR-NET, Japanese Registry of Neuroendovascular Therapy; AVM, arteriovenous malformation; DAVF, dural arteriovenous fistula; JSNET, Japanese Society of Neuroendovascular Therapy